- 1Dec

Changes to NICE’s cost-effectiveness thresholds confirmed
This change aims to enhance the operating environment for pharmaceutical companies in the UK, supporting innovation [...]
- 1Dec

Landmark UK-US trade deal
On Wednesday, October 1, 2025, the UK-US landmark deal was announced on the government website. Tens [...]
- 1Dec

Navigating the challenges of Clinical Trials in Rare Disease
Designing clinical trials for rare diseases requires balancing scientific rigour with practical realities. A key challenge [...]
- 18Nov

Companies granted third extension to VPAG 2026
The ABPI and the government have extended the deadline for companies to announce their exit from [...]
- 10Nov

Who will truly benefit? MFN deals
AstraZeneca’s Agreement with the U.S. Government AstraZeneca announced a landmark agreement with the Trump administration to [...]
- 17Oct

True synergistic combination therapy
Over the last few weeks, I’ve noticed several online discussions about Combination Therapies. Having supported a [...]
- 16Oct

The UK’s ILAP Is accelerating medical innovation and it’s happening now!
The Innovative Licensing and Access Pathway (ILAP), launched by the MHRA in 2021 and re-launched in [...]
- 15Oct

We are excited to announce that we are now members of the BIA
The BioIndustry Association (BIA) is the award-winning trade association for the innovative life sciences and biotech [...]
- 14Oct

Implications for England’s proposed cost-effectiveness threshold increase
Background: NHS Drug Pricing and US-UK Relations Recent reports confirm that the UK is considering raising [...]
- 11Oct

A crucial step forward in suicide prevention
This week, coinciding with World Mental Health Day, The Royal Foundation announced a £1 million contribution [...]


